Document is current
Any future updates will be listed below
-
Authors
Ortega, Emilio https://orcid.org/0000-0002-2217-8905
Redondo-Antón, Jennifer https://orcid.org/0000-0003-2661-5866
Díaz-Cerezo, Silvia https://orcid.org/0000-0001-6351-818X
Rubio-de Santos, Miriam https://orcid.org/0000-0001-7393-6334
Romera, Irene https://orcid.org/0000-0002-1345-9799
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 30 April 2025
First Online: 19 May 2025
Declarations
:
: Emilio Ortega has received institutional grants from Eli Lilly and Novo Nordisk, consulting fees from Eli Lilly, honoraria for presentations, manuscript writing or educational events from Eli Lilly and Novo Nordisk, and support for meeting attendance and/or travel from Eli Lilly and Novo Nordisk. Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Miriam Rubio-de Santos, and Irene Romera are employees and minor shareholders of Eli Lilly and Company, Spain.
: As this was an observational study that used previously collected data and did not impose any form of intervention, and the data were previously deidentified/anonymised to protect participant privacy, a formal Consent to Release Information form was not required. Permission was obtained to access and use data from this database. The study protocol was approved by the ethical review board of Hospital Clinic (Barcelona, Spain) (approval code HCB/2023/0287, dated 16 May 2023), as required by Spanish regulations related to healthcare observational studies. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of Spain.
